Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]

OncoAlert and ecancer - ESMO 2021 Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer

Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center...

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer ( Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas )

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple...

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple...

Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first...

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-line treatment of unresectable mCRC patients ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs...

Prof Nadia Harbeck - University of Munich, Munich, Germany

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC ( Prof Nadia Harbeck - University of Munich, Munich, Germany )

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally...

Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )

B-cell maturation antigen targeted CD3-engaging bispecific molecule for...

Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville...

$B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )$

MRD-guided therapy debate

Prof Ola Landgren - University of Miami, Miami, USA

MRD-guided therapy debate ( Prof Ola Landgren - University of Miami, Miami, USA )

KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in...

Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA

KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma ( Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA )

More from ecancer